Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of gemcitabine plus carboplatin in advanced urothelial transitional cell carcinoma
ISRCTN88259320Phase 2Completed
- Sponsor
- Zhejiang University School of Medicine
- Start
- Jan 2003
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and carboplatin in transitional cell carcinoma (TCC), sponsored by Zhejiang University School of Medicine. Primary endpoints: Objective response rate and Tolerability. Started Jan 2003; status: completed.
02
Drugs
gemcitabinecarboplatin
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on ISRCTN88259320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN88259320.